Sorrento Therapeutics Inc Sorrento’s (NASDAQ: SRNE) Subsidiary Scilex Gets an sNDA Approval for ZTlido Sorrento Therapeutics, Inc. (NASDAQ: SRNE) disclosed that Scilex Holding has got a supplemental new drug application (sNDA) authorization from the FDA for ZTlido. Scilex is the 99% owned unit of Sorrento Therapeutics.
Breaking News Sorrento Therapeutics's (NASDAQ: SRNE) SmarPharm Receives Contract From DARPA-JPEO Sorrento Therapeutics’s (NASDAQ: SRNE) fully-owned unit SmartPharm Therapeutics has accepted a contract to provide quick protection measures against COVID-19. The contract was granted to SmartPharm by DARPA and is co-supported by JPEO-CBRND. The DRAPA/JPEO deal will offer support to speed up
Investments Sorrento Therapeutics Inc (NASDAQ: SRNE) Rallies By Over 90% After Rejecting A Buy-Out Offer Sorrento Therapeutics Inc (NASDAQ: SRNE) was one of the biggest gainers in Monday’s trading session. The stock closed the day with gains of 94.37%. This followed news that the company had rejected a buyout offer from two unnamed companies. The two companies
